Citations

Showing 10 of 108094 citations.

Cochlear Implantation After Intralabyrinthine Schwannoma Microsurgical Resection
Goates, Andrew J. , Nassiri, Ashley M. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | September 27, 2022 | Volume: 44 | Issue: 1 | Pages: e51-e52

10.1097/mao.0000000000003705 | PMID 36167026 Get It

Abstract Cochlear implantation after microsurgical resection of intralabyrinthine schwannomas has shown promising results in a limited number of small studies with safe and favorable outcomes. Cochlear implantation is a mainstream treatment for advanced bilateral sensorineural hearing loss and, more recently, has been applied to patients with single-sided deafness. The case presented is a 66-year-old gentleman with a history of progressive right-sided sensorineural hearing loss and bothersome tinnitus with a right intralabyrinthine schwannoma involving the semicircular canals, vestibule, and basal turn of the cochlea. The authors describe concomitant cochlear implantation after microsurgical resection of an intralabyrinthine schwannoma. Intralabyrinthine schwannomas represent an uncommon subtype of benign tumors arising from the terminal branches of the vestibulocochlear nerve. Symptoms often include sensorineural hearing loss, dizziness, and tinnitus, and in this location, symptoms often arise at a small tumor size. In this featured case, we present a patient who underwent gross total tumor resection and cochlear implantation for hearing rehabilitation and treatment of tinnitus. Six months after surgery, the patient achieved good device performance, scoring 46% on consonant–nucleus–consonant word testing and 66% on AzBio sentence testing, and subjective improvement in his tinnitus.
Cardiogenic shock severity and mortality in patients receiving venoarterial extracorporeal membrane oxygenator support
Jentzer, Jacob C. , Baran, David A. , Diepen, Sean van , Radosevich, Misty A., Yalamuri, Suraj , Rycus, Peter , Tonna, Joseph E. , van Diepen, Sean , Radosevich, Misty, Tonna, Joseph E. , Jentzer, Jacob C , Baran, David A , Bohman, J. Kyle , Drakos, Stavros G.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | September 27, 2022 | Volume: 11 | Issue: 12 | Pages: 891-903

10.1093/ehjacc/zuac119 | PMID 36173885 Get It

Abstract Aims Shock severity predicts mortality in patients with cardiogenic shock (CS). We evaluated the association between pre-cannulation Society for Cardiovascular Angiography and Intervention (SCAI) shock classification and mortality among patients receiving venoarterial (VA) extracorporeal membrane oxygenation (ECMO) support for CS. Methods and results We included Extracorporeal Life Support Organization (ELSO) Registry patients from 2010 to 2020 who received VA ECMO for CS. SCAI shock stage was assigned based on hemodynamic support requirements prior to ECMO initiation. In-hospital mortality was analyzed using multivariable logistic regression. We included 12 106 unique VA ECMO patient runs with a median age of 57.9 (interquartile range: 46.8, 66.1) years and 31.8% were females; 3472 (28.7%) were post-cardiotomy. The distribution of SCAI shock stages at ECMO initiation was: B, 821 (6.8%); C, 7518 (62.1%); D, 2973 (24.6%); and E, 794 (6.6%). During the index hospitalization, 6681 (55.2%) patients died. In-hospital mortality increased incrementally with SCAI shock stage (adjusted OR: 1.24 per SCAI shock stage, 95% CI: 1.17–1.32, P < 0.001): B, 47.5%; C, 52.8%; D, 60.8%; E, 65.1%. A higher SCAI shock stage was associated with increased in-hospital mortality in key subgroups, although the SCAI shock classification was only predictive of mortality in non-surgical (medical) CS and not in post-cardiotomy CS. Conclusion The severity of shock prior to cannulation is a strong predictor of in-hospital mortality in patients receiving VA ECMO for CS. Using the pre-cannulation SCAI shock classification as a risk stratification tool can help clinicians refine prognostication for ECMO recipients and guide future investigations to improve outcomes.
Cellular senescence is increased in airway smooth muscle cells of elderly persons with asthma
Aghali, Arbi , Khalfaoui, Latifa, Lagnado, Anthony B. , Drake, Li Y. , Teske, Jacob J. , Pabelick, Christina M. , Passos, João F. , Prakash, Y. S. , Prakash, Y S , Drake, Li , Pabelick, Christina M , Passos, João F , Teske, Jacob J

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 27, 2022 | Volume: 323 | Issue: 5 | Pages: L558-L568

10.1152/ajplung.00146.2022 | PMID 36166734 Get It

Senescent cells can drive age-related tissue dysfunction partially via a senescence-associated secretory phenotype (SASP) involving proinflammatory and profibrotic factors. Cellular senescence has been associated with a structural and functional decline during normal lung aging and age-related diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Asthma in the elderly (AIE) represents a major healthcare burden. AIE is associated with bronchial airway hyperresponsiveness and remodeling, which involves increased cell proliferation and higher rates of fibrosis, and resistant to standard therapy. Airway smooth muscle (ASM) cells play a major role in asthma such as remodeling via modulation of inflammation and the extracellular matrix (ECM) environment. Whether senescent ASM cells accumulate in AIE and contribute to airway structural or functional changes is unknown. Lung tissues from elderly persons with asthma showed greater airway fibrosis compared with age-matched elderly persons with nonasthma and young age controls. Lung tissue or isolated ASM cells from elderly persons with asthma showed increased expression of multiple senescent markers including phospho-p53, p21, telomere-associated foci (TAF), as well as multiple SASP components. Senescence and SASP components were also increased with aging per se. These data highlight the presence of cellular senescence in AIE that may contribute to airway remodeling.
Neuroimmune proteins can differentiate between tauopathies
Cherry, Jonathan D. , Baucom, Zach H., Eppich, Kaleb G., Kirsch, Daniel , Dixon, Erin, Crary, John F. , McKee, Ann C. , Tripodis, Yorghos , Bieniek, Kevin F. , Farrell, Kurt , Whitney, Kristen R. , Uretsky, Madeline , Dickson, Dennis W.

Mayo Clinic

No container title available | September 27, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2092813/v1 Get It

AbstractBackgroundTauopathies are a group of neurodegenerative diseases where there is pathologic accumulation of hyperphosphorylated tau protein (ptau). The most common tauopathy is Alzheimer’s disease (AD), but chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD) are significant health risks as well. Currently, it is unclear what specific molecular factors might drive each distinct disease and represent therapeutic targets. Additionally, there is a lack of biomarkers that can differentiate each disease in life. Recent work has suggested that neuroinflammatory changes might be specific among distinct diseases and offers a novel resource for mechanistic targets and biomarker candidates.MethodsTo better examine each tauopathy, a 71 immune-related protein multiplex ELISA panel was utilized to analyze anterior cingulate grey matter from 127 individuals neuropathologically diagnosed with AD, CTE, PSP, CBD, and AGD. A partial least square regression analysis was carried out to perform unbiased clustering and identify proteins that are distinctly correlated with each tauopathy correcting for age and gender. Receiver operator characteristic and binary logistic regression analyses were then used to examine the ability of each candidate protein to distinguish diseases. Validation in postmortem cerebrospinal fluid (CSF) from 15 AD and 14 CTE cases was performed to determine if candidate proteins could act as possible novel biomarkers.ResultsFive clusters of immune proteins were identified and compared to each tauopathy to determine if clusters were specific to distinct disease. Each cluster was found to correlate with either CTE, AD, PSP, CBD, or AGD. When examining which proteins were the strongest driver of each cluster, it was observed the most distinctive protein for CTE was 6Ckine, AD was FLT3L, and PSP was IL13. Individual proteins that were specific to CBD and AGD were not observed. 6Ckine was observed to be elevated in CTE CSF compared to AD cases (p = 0.02), further validating the use as possible biomarkers.ConclusionsOverall, these results highlight that different neuroinflammatory responses might underlie unique mechanisms in related neurodegenerative pathologies. Additionally, the use of distinct neuroinflammatory signatures could help differentiate between tauopathies and act as novel biomarker candidates.
TurnoveR: A Skyline External Tool for Analysis of Protein Turnover in Metabolic Labeling Studies
Basisty, Nathan , Shulman, Nicholas , Wehrfritz, Cameron, Marsh, Alexandra N. , Shah, Samah , Rose, Jacob , Ebert, Scott M. , Miller, Matthew J. , Rabinovitch, Peter S. , Adams, Christopher M. , MacCoss, Michael J. , MacLean, Brendan , Ebert, Scott, MacCoss, Michael J , Schilling, Birgit , Ebert, Scott M. , Adams, Christopher M , Basisty, Nathan , Dai, Dao‐Fu

Mayo Clinic

Journal of Proteome Research | September 27, 2022 | Volume: 22 | Issue: 2 | Pages: 311-322

10.1021/acs.jproteome.2c00173 | PMID 36165806 Get It

Modification of social determinants of health by critical illness and consequences of that modification for recovery: an international qualitative study
McPeake, Joanne , Boehm, Leanne M. , Hibbert, Elizabeth , Hauschildt, Katrina , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , McCartney, Judith, Meyer, Joel , Montgomery-Yates, Ashley , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , Sevin, Carla M. , Haines, Kimberley , Quasim, Tara , Mikkelsen, Mark E.

Mayo Clinic

BMJ Open | September 27, 2022 | Volume: 12 | Issue: 9 | Pages: e060454

10.1136/bmjopen-2021-060454 | PMID 36167379 Get It

Objectives Social determinants of health (SDoH) contribute to health outcomes. We identified SDoH that were modified by critical illness, and the effect of such modifications on recovery from critical illness. Design In-depth semistructured interviews following hospital discharge. Interview transcripts were mapped against a pre-existing social policy framework: money and work; skills and education; housing, transport and neighbourhoods; and family, friends and social connections. Setting 14 hospital sites in the USA, UK and Australia. Participants Patients and caregivers, who had been admitted to critical care from three continents. Results 86 interviews were analysed (66 patients and 20 caregivers). SDoH, both financial and non-financial in nature, could be negatively influenced by exposure to critical illness, with a direct impact on health-related outcomes at an individual level. Financial modifications included changes to employment status due to critical illness-related disability, alongside changes to income and insurance status. Negative health impacts included the inability to access essential healthcare and an increase in mental health problems. Conclusions Critical illness appears to modify SDoH for survivors and their family members, potentially impacting recovery and health. Our findings suggest that increased attention to issues such as one’s social network, economic security and access to healthcare is required following discharge from critical care.
The feasibility and value of assessing patient‐reported outcomes in pulmonary arterial hypertension
DuBrock, Hilary M. , Reddy, Yogesh N.V. , Durst, Louise A., Schroeder, Darrell R. , Park, Grace , Kane, Garvan C. , Kushwaha, Sudhir S. , McCully, Robert B. , Murphy, Joseph G. , Anand, Vidhu , Krowka, Michael J. , Reddy, Yogesh N, Frantz, Robert P , Nishimura, Rick , DuBrock, Hilary M , Schroeder, Darrell , Cajigas, Héctor , Frantz, Robert P.

Mayo Clinic

Pulmonary Circulation | September 27, 2022 | Volume: 12 | Issue: 4 | Pages: No page available

10.1002/pul2.12143 | PMID 36262468 Get It

AbstractPulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that negatively impacts health‐related quality of life (HRQOL). The PAH‐symptoms and impact (PAH‐SYMPACT) questionnaire is a validated disease‐specific patient‐reported outcome (PRO) instrument that assesses a patient's symptoms and the impact of PAH and its treatment on well‐being. We performed a single‐center prospective cohort study of patients with PAH to determine the feasibility of assessing PROs in clinical practice and to determine the association between PAH‐SYMPACT domains and clinical characteristics and outcomes. One hundred and ten patients completed the 1‐day version of the PAH‐SYMPACT questionnaire which consists of 22 Likert‐scale questions that assess HRQOL across four domains: cardiopulmonary (CP) symptoms, cardiovascular (CV) symptoms, physical impact (PI), and cognitive and emotional (CE) impact. Higher scores indicate worse HRQOL. Patients were predominantly female (n = 86, 78%) with a mean age of 57.8 ± 16.2 years. While several patient characteristics were associated with CP and PI domains, few were associated with CV and CE domains. PI and CE impact scores were associated with recent hospitalizations and mortality and CE impact score was independently associated with an increased risk of death after adjustment for disease severity (hazard ratio: 3.29, 95% confidence interval: 1.56–6.91, p = 0.002). In conclusion, the assessment of PROs in clinical practice using the PAH‐SYMPACT questionnaire is both feasible and valuable. PAH‐SYMPACT scores have independent prognostic value and are not adequately reflected by traditional measures of disease severity. These findings underscore the importance of assessing HRQOL in clinical practice.
The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis
Sonbol, Mohamad Bassam , Pathak, Surabhi , Firwana, Belal , Botrus, Gehan , Almader‐Douglas, Diana , Ahn, Daniel H. , Starr, Jason S. , Jones, Jeremy , Stucky, Chee‐Chee , Smoot, Rory L. , Bekaii‐Saab, Tanios , Almader-Douglas, Diana, Riaz, Irbaz Bin , Smoot, Rory L , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Jones, Jeremy C , Siddiqi, Rabbia , Usón, Pedro Luiz Serrano , Borad, Mitesh J.

Mayo Clinic

The Oncologist | September 27, 2022 | Volume: 27 | Issue: 12 | Pages: 1034-1040

10.1093/oncolo/oyac212 | PMID 36239399 Get It

Abstract Background Despite multiple randomized trials, the role of perioperative chemotherapy in colorectal cancer liver metastasis (CRLM) is still under debate. In this systematic review and network meta-analysis (NMA), we aim to evaluate the efficacy of perioperative systemic therapies for patients with CRLM. Methods We searched various databases for abstracts and full-text articles published from database inception through May 2021.We included randomized controlled trials (RCTs) comparing the addition of perioperative (post, pre, or both) systemic therapies to surgery alone in patients with CRLM. The outcomes were compared according to the chemotherapy regimen using a random effects model. Outcomes of interest included disease-free survival (DFS) and overall survival (OS). Results Seven RCTs with a total of 1504 patients with CRLM were included. Six studies included post-operative treatment and one evaluated perioperative (pre- and postoperative) therapy. Fluoropyrimidine-based chemotherapy was the most used systemic therapy. NMA showed benefit of adding perioperative therapy to surgery in terms of DFS (HR 0.73, 95% CI 0.63 to 0.84). However, these findings did not translate into a statistically significant OS benefit (HR 0.88, 95% CI 0.74 to 1.05). NMA did not show any advantage of one regimen over another including oxaliplatin or irinotecan. Conclusions This systematic review and NMA of 7 RCTs found that the addition of perioperative systemic treatment for resectable CRLM could improve disease-free survival but not overall survival. Based on the findings, addition of perioperative treatment in resectable CRLM should be individualized weighing the risks and benefits.
Diet and carcinogenesis of gastric cancer
Maddineni, Gautam , Xie, Jesse J. , Brahmbhatt, Bhaumik , Mutha, Pritesh

Mayo Clinic

Current Opinion in Gastroenterology | September 27, 2022 | Volume: 38 | Issue: 6 | Pages: 588-591

10.1097/mog.0000000000000875 | PMID 36165035 Get It

Purpose of review Several recent studies have corroborated a strong association between diet and gastric cancer risk; investigators have also identified dietary factors that protect against gastric cancer. This review summarizes the literature on this topic and guides future research directions. Recent findings High-salt intake disrupts the gastric mucosal defense barrier, promoting Helicobacter pylori colonization and penetration of other carcinogenic compounds. Processed foods, processed meats, red meat, alcohol, foods with high dietary fat, and dietary cholesterol increase the risk of gastric carcinogenesis. On the other hand, increased consumption of fruits, vegetables, whole grains, nuts, and a low-salt diet may offer a protective effect. Summary Despite decreases in gastric cancer incidence because of increased identification and treatment of H. pylori, gastric cancer remains one of the most common cancers worldwide with a high mortality rate. This disturbing statistic highlights the importance of reducing and eliminating other risk factors for gastric cancer. There is a strong body of evidence that alcohol, processed foods, high salt intake, high fat intake, and foods with animal products (meats, eggs, and dairy) increase the risk of gastric cancer. A diet that is high in whole grains, fruits, vegetables, nuts and is low in salt may reduce the risk of gastric cancer.
Predictors of histologic response to dietary therapy in eosinophilic oesophagitis
Wang, Lillian , Mara, Kristin C. , Wu, Tsung‐Teh, Smyrk, Thomas C. , Katzka, David A. , Alexander, Jeffrey A. , Mara, Kristin C , Ravi, Karthik

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 27, 2022 | Volume: 56 | Issue: 10 | Pages: 1444-1452

10.1111/apt.17221 | PMID 36163696 Get It

SummaryBackgroundDietary therapy successfully treats eosinophilic oesophagitis (EoE), but limited data exist on predictors of patient response.AimsTo determine response rates and to identify predictors of histologic response to elimination diets in adults with EoEMethodsThis was a retrospective, single‐centre study of adults with PPI‐refractory EoE undergoing dietary therapy with six food elimination diet (SFED) or extended six food elimination diet (ExSFED) in an outpatient setting from January 2012 to January 2019. Patient demographics, radiologic and endoscopic findings, endoscopic reference (EREF) scores, histology and symptoms were evaluated before and after food elimination. Histologic response was assessed via tissue obtained from endoscopically‐guided biopsy or Cytosponge. Dietary therapy adherence was assessed via structured phone interview. Multivariable logistic regression analysis was performed to identify predictors of dietary response.ResultsWe included 68 patients, of whom 62% had a histologic response to dietary therapy (81% to SFED, 19% to ExSFED). Median duration of follow‐up was 45 months (IQR, 34–53 months). On multivariable analysis, higher pre‐SFED EREF score was the only variable associated with dietary non‐response (OR 0.07, 95% CI 0.49, 0.98; p = 0.04).ConclusionsIn adults with EoE, histologic dietary non‐response to SFED was associated with a higher pre‐SFED EREF score, suggesting that fixed structural disease may predict dietary non‐response. Our additional observations of poor correlation between symptomatic and histologic flares, and identification of ExSFED responders, suggest that histologic confirmation should be sought before committing patients to lifelong dietary changes. We also recommend the consideration of restricting legumes and corn in SFED non‐responders as ExSFED detected additional dietary responders.